Sisram Medical Achieves Remarkable Growth in Q3 2025 Across Key Markets and Core Sectors

Sisram Medical Delivers Strong Performance in Q3 2025

Sisram Medical Ltd, listed as 1696.HK, has reported outstanding growth figures for the third quarter of 2025, showcasing its effective strategies and strong market presence, particularly in Asia. This report highlights Sisram's impressive financial performance, innovative product launches, and expanded market reach, which together underpin the company's status as a leader in the medical aesthetics industry.

Strong Revenue Growth

In the latest quarterly update, Sisram Medical indicated a remarkable double-digit revenue growth compared to Q3 of last year, fueled by an increase in new orders. The company has witnessed particularly strong demand in key markets, including China, South Korea, and Thailand. This growth signals not only robust economic momentum in these regions but also the effectiveness of Sisram's targeted marketing strategies and localized business models.

Continued Success in Energy-Based Devices (EBD)

The EBD segment, a cornerstone of Sisram's portfolio, continues to thrive. The Alma Harmony, an award-winning platform that launched globally in March 2025, saw a significant uptick in orders. This strong performance was complemented by the Soprano family of laser devices, especially after the successful launch of the latest Soprano model in China, which contributed to substantial new orders.

Expanding the Injectables Portfolio

Sisram's injectables business has emerged as a key growth driver. Recently, the company announced that DAXXIFY, a groundbreaking botulinum toxin type A product, received approval from the National Medical Products Administration in China. This marks a significant milestone, as DAXXIFY is the first product of its kind in the region to utilize proprietary Peptide Exchange Technology, expected to significantly enhance the injectables market and further invigorate the company’s sales pipeline. The strategic preparations for DAXXIFY's launch are well underway, which is set to inject fresh momentum into Sisram's overall injectables segment.